PROP1
Basic information
Region (hg38): 5:177992235-177996242
Links
Phenotypes
GenCC
Source:
- pituitary hormone deficiency, combined, 2 (Definitive), mode of inheritance: AR
- pituitary hormone deficiency, combined, 2 (Definitive), mode of inheritance: AR
- pituitary hormone deficiency, combined, 2 (Strong), mode of inheritance: AR
- pituitary hormone deficiency, combined, 2 (Strong), mode of inheritance: AR
- panhypopituitarism (Supportive), mode of inheritance: AR
- combined pituitary hormone deficiencies, genetic form (Supportive), mode of inheritance: AD
- hypothyroidism due to deficient transcription factors involved in pituitary development or function (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Pituitary hormone deficiency, combined, 2 | AR | Endocrine | Hormone replacement therapy can be effective to treat multiple endocrinological deficiencies (eg, GH and thyroid hormone deficiency); Individuals may develop ACTH deficiency, and may require treatment including "stress dose steroids"; Medical interventions may be necessary to induce puberty | Endocrine | 6046325; 745452; 9661653; 9768691; 9462743; 10084575; 920061; 11134108; 10634415; 11549674; 11549703; 15472175; 15531542; 20301521; 20381582; 20395664; 22024773; 22111336; 22286799 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (17 variants)
- Pituitary hormone deficiency, combined, 2 (6 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PROP1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 101 | 103 | ||||
missense | 28 | 39 | ||||
nonsense | 11 | |||||
start loss | 3 | |||||
frameshift | 10 | 14 | 26 | |||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 7 | |||||
splice region | 9 | 1 | 10 | |||
non coding | 20 | 10 | 37 | |||
Total | 18 | 31 | 42 | 124 | 14 |
Highest pathogenic variant AF is 0.0000131
Variants in PROP1
This is a list of pathogenic ClinVar variants found in the PROP1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-177992241-G-A | Pituitary hormone deficiency, combined, 2 | Uncertain significance (Jan 13, 2018) | ||
5-177992275-A-T | Pituitary hormone deficiency, combined, 2 | Uncertain significance (Jan 13, 2018) | ||
5-177992290-G-A | Pituitary hormone deficiency, combined, 2 | Benign (Jan 12, 2018) | ||
5-177992355-C-T | Pituitary hormone deficiency, combined, 2 | Benign (Jan 12, 2018) | ||
5-177992586-A-G | Pituitary hormone deficiency, combined, 2 | Benign (Sep 22, 2018) | ||
5-177992589-G-A | Likely benign (Apr 09, 2021) | |||
5-177992657-C-T | Pituitary hormone deficiency, combined, 2 | Conflicting classifications of pathogenicity (Nov 08, 2018) | ||
5-177992672-G-A | Pituitary hormone deficiency, combined, 2 | Uncertain significance (Jan 12, 2018) | ||
5-177992719-G-C | Uncertain significance (Jun 28, 2022) | |||
5-177992735-G-A | Inborn genetic diseases | Uncertain significance (Oct 20, 2024) | ||
5-177992737-C-CT | Pituitary hormone deficiency, combined, 2 | Uncertain significance (May 26, 2017) | ||
5-177992745-G-T | Likely benign (Jul 23, 2022) | |||
5-177992754-A-C | Likely benign (Nov 18, 2021) | |||
5-177992754-A-G | Conflicting classifications of pathogenicity (Apr 27, 2020) | |||
5-177992754-A-T | Likely benign (Nov 04, 2020) | |||
5-177992756-G-C | Inborn genetic diseases | Uncertain significance (Aug 14, 2024) | ||
5-177992757-G-A | Likely benign (Dec 24, 2020) | |||
5-177992758-G-T | PROP1-related disorder | Uncertain significance (Jan 25, 2024) | ||
5-177992760-T-C | Likely benign (Sep 29, 2023) | |||
5-177992760-T-G | not specified • Pituitary hormone deficiency, combined, 2 | Conflicting classifications of pathogenicity (Jan 12, 2018) | ||
5-177992760-TG-T | Pituitary hormone deficiency, combined, 2 | Likely pathogenic (Jul 16, 2023) | ||
5-177992760-T-TG | Pituitary hormone deficiency, combined, 2 | Conflicting classifications of pathogenicity (Nov 19, 2022) | ||
5-177992761-G-A | not specified | Uncertain significance (Sep 25, 2024) | ||
5-177992763-G-A | Likely benign (Jan 31, 2020) | |||
5-177992766-G-A | Pituitary hormone deficiency, combined, 2 | Likely benign (Jan 24, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PROP1 | protein_coding | protein_coding | ENST00000308304 | 3 | 4008 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0877 | 0.875 | 125675 | 0 | 73 | 125748 | 0.000290 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.248 | 130 | 138 | 0.941 | 0.00000883 | 1416 |
Missense in Polyphen | 50 | 44.389 | 1.1264 | 423 | ||
Synonymous | -0.570 | 60 | 54.6 | 1.10 | 0.00000314 | 494 |
Loss of Function | 1.78 | 3 | 8.63 | 0.348 | 6.40e-7 | 73 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000293 | 0.000293 |
Ashkenazi Jewish | 0.000198 | 0.000198 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000926 | 0.0000924 |
European (Non-Finnish) | 0.000513 | 0.000501 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000997 | 0.0000980 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Possibly involved in the ontogenesis of pituitary gonadotropes, as well as somatotropes, lactotropes and caudomedial thyrotropes.;
Intolerance Scores
- loftool
- 0.253
- rvis_EVS
- 0.28
- rvis_percentile_EVS
- 71.27
Haploinsufficiency Scores
- pHI
- 0.0996
- hipred
- N
- hipred_score
- 0.212
- ghis
- 0.412
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.488
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Prop1
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Zebrafish Information Network
- Gene name
- prop1
- Affected structure
- prolactin secreting cell
- Phenotype tag
- abnormal
- Phenotype quality
- spatial pattern
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;blood vessel development;central nervous system development;dorsal/ventral pattern formation;cell migration;hypothalamus cell differentiation;negative regulation of apoptotic process;positive regulation of transcription by RNA polymerase II;hypophysis morphogenesis;canonical Wnt signaling pathway;somatotropin secreting cell differentiation
- Cellular component
- nucleus;transcription factor complex
- Molecular function
- RNA polymerase II distal enhancer sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;protein binding;beta-catenin binding;protein C-terminus binding